AIM ImmunoTech Inc.

AMEX: AIM · Real-Time Price · USD
0.09
-0.03 (-23.53%)
At close: Apr 04, 2025, 10:10 AM
-23.53%
Bid n/a
Market Cap 6.52M
Revenue (ttm) 170K
Net Income (ttm) -17.32M
EPS (ttm) -0.31
PE Ratio (ttm) -0.31
Forward PE n/a
Analyst Buy
Ask n/a
Volume 2,305,517
Avg. Volume (20D) 1,121,082
Open 0.11
Previous Close 0.12
Day's Range 0.06 - 0.11
52-Week Range 0.03 - 0.52
Beta 0.76

About AIM

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, n...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 12, 1996
Employees 21
Stock Exchange AMEX
Ticker Symbol AIM
Full Company Profile

Advertisement

Analyst Forecast

According to 2 analyst ratings, the average rating for AIM stock is "Buy." The 12-month stock price forecast is $2.75, which is an increase of 2797.79% from the latest price.

Stock Forecasts
3 weeks ago
-25%
AIM ImmunoTech shares are trading lower after the ... Unlock content with Pro Subscription
2 months ago
+5.84%
AIM ImmunoTech shares are trading higher after the company announced it will not proceed with an offering under its Form S-1 registration statement until after filing its annual report.